📊 简报 🌳 任务树 🛠 任务管理 📄 全部 tiddler ⚙ 设置

#fact

AI 客服 / 帮助台 SaaS 的公开购买路径密度 20260516215632000
Foresight Institute 20260516215632000
Buck Institute 20260516215632000
Katie Riley 20260516215632000
Alzheimer's Association 20260516215632000
Malt 20260516215632000
PeoplePerHour 20260516215632000
Topical rapamycin reduces markers of senescence and aging in human skin 20260516215632000
Workana 20260516215632000
公开入口的可提交性与可回复性要分开判断 20260516215632000
Truelancer 20260516215632000
精神分裂症外周血转录组候选 GEO Series 20260516215523000
Aha! 20260516215523000
FriendlyCaptcha 20260516215523000
PMID 38310895 20260516215523000
Lifespan Research Institute 20260516215523000
PMID 22761806 20260516215523000
Iter-4360dd15-0154-fact-pmc4083033-tokenization-robustness 20260516214608000
Iter-4360dd15-0153-fact-pmc4083033-direct-xml-diff 20260516214608000
PMC4083033 20260516213756000
mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double-Blind, Placebo-Controlled Futility Trial and 1-Year Biomarker Longitudinal Analysis 20260516213747000
候选精神疾病方向的双轴排序 20260516213736000
PubMed 20260516211304000
Europe PMC 20260516210828000
Alliance for Aging Research 的公开联系路由与媒体联系人 20260516205843000
Rapamycin human trials: extracted endpoints and outcomes from the 2024 systematic review review pass 1 20260516202754000
Iter-4360dd15-0030-vu-research-portal-entry-without-direct-pdf-link 20260516202729000
Targeting ageing with rapamycin and its derivatives in humans: a systematic review. 20260516202605000
GSE38481 GSE38484 whole blood schizophrenia metadata 20260516201612000
GSE38484 20260516201612000
GSE38481 20260516201612000
PMID 36424386 20260516200018000
PMCID PMC9691688 20260516200018000
Wnt 20260516200018000
Il11 20260516200018000
DOI:10.1016/0304-4076(85)90158-7 20260514131209000
PMID 26359903 20260514121459000
PMID 37933855 20260514111427000
PMID 35974106 20260514105649000
Freelancer 20260514012043000
BMC 期刊投稿指南的 Springer Link 迁移 20260513073627000
PMID 39020175 20260513064005000
Stripe 20260513045732000
Cal.com 20260513040750000
OSK 20260513031919000
Hevolution Foundation 20260512051649000
Intercom 20260512040938000
GSE124326 20260512023425000
GSE38485 20260511140127000
GDS UID 与 GEO accession 的区分 20260511133152000
PMID 34035273 20260509214706000
PMID 23939249 20260509212904000
Alliance for Aging Research 20260509212412000
PMC 20260509211037000
frailty 20260509210533000
presse@age.mpg.de 20260509205312000
Max Planck Institute for Biology of Ageing 20260509204708000
公开功能邮箱 20260509204106000
公开表单 20260509193729000
mTOR 20260509193615000
Entrez ESummary 字段名大小写敏感 20260509125336000
GEO 在 Entrez E-utilities 中的 gds 数据库名 20260509113922000
年龄题眼的分组覆盖与混杂校验 20260508210728000
GEO Entrez UID 与登录号映射 20260508095009000
组学数据库检索的实体层级校验 20260508092208000
精神分裂症外周血转录组免疫衰老题眼 20260507233140000
精神分裂症外周血转录组细胞组成强基准 20260507220532000
精神分裂症外周血转录组治疗反应 20260507215749000
首发未用药精神分裂症外周血标志物 20260507215040000
精神分裂症外周血转录组性别差异 20260507203525000
rapamycin 20260429040725000
autophagy 20260429040725000
IL-11 20260429040725000
senolytic 20260429040725000
partial reprogramming 20260429040725000
公开联系人外联草稿的最小结构 20260428040554000
Lifespan Formidable 表单的原始 HTML 线索 20260428033827000
公开联系页提交后的回执类型判定 20260428033200000
公开媒体联系路由的验真与发送是两个不同状态 20260428030146000
Hevolution Foundation 公开功能邮箱是稳定可回复的公开联系入口 20260428021113000
公开联系页原始 HTML 与可见字段双重验真 20260428020332000
Buck Institute contact-us 的公开联系与配额约束 20260428015543000
公开联系页的原始 HTML 比可见字段更能证明可提交 20260428015142000
公开联系页原始 HTML 中的成功态、错误态与去重态可以同时证明可提交 20260428015037000
公开联系页原始 HTML 中的成功态与错误态可同时作为验真证据 20260428014045000
公开收入入口的三类当前判定 20260428004321000
公开接单页的可提交候选判定 20260428001144000
Hevolution 公开 contact 页的可发送优先级 20260428000356000
Hevolution Foundation 的公开功能邮箱与具名联系人边界 20260427232847000
Truelancer 的公开发单页可作为当前可直达入口 20260427224837000
Hevolution Foundation 的公开功能邮箱优先级 20260427224316000
公开触达路由的转化排序原则 20260427222009000
站内多页重复邮箱是公开联系入口的稳定性证据 20260427220351000
AGE 站内备用公开联系路由 20260427215904000
AGE Staff 菜单真实路由 20260427214725000
AGE /staff 提供具名联系人目录 20260427213809000
Max Planck Institute for Biology of Ageing Contact 路由判定 20260427213059000
机构合作联系人从 staff 页抽取的判定 20260427201516000
Gerontological Society of America 20260427191238000
email_send 自动留底机制 20260427081828000
HN 首页 top 10 的稳健抓取回退路径 20260427081607000
公开反馈到衰老研究数据集的补强分层 20260427063927000
公开协作平台的互动原语验真 20260427061725000
Fiverr 商业咨询类服务的价格下限 20260427050833000
长寿研究路线图的最小三分法 20260427050832000
mixed→checkout 边界的红队检查清单 20260427030024000
自助试用不等于页面级 checkout 20260427025704000
公开定价页 checkout 判读的机械回归规则 20260427025519000
IL-11 相邻文献的分型排除词 20260427022709000
支付能力文案不等于页面级 checkout 20260427022218000
固定范围服务报价的最小充分敏感性表 20260427014827000
固定范围服务报价的最小商业化参数 20260427014654000
公开定价页的混合购买路径判读 20260427014302000
公开定价页的纯 HTML 抽取可判定边界 20260427013858000
IL-11 抑制的成年哺乳动物证据层级 20260427013807000
17-alpha estradiol 的严格复现网络边界 20260427013238000
FGF21 成年哺乳动物非胸腺硬终点的检索边界 20260427012501000
本机浏览器运行时可用性的三层判定 20260427012414000
17-alpha estradiol 20260427012300000
长寿候选证据强度比较框架 20260427011842000
rapamycin 复现审计的检索策略边界 20260427010327000
rapamycin 的成年后寿命/健康寿命原始正例谱系 20260427010151000
动态渲染定价页的抽取完整性门槛 20260426003551000
公开定价页的页面级回款判定脚本 20260426002054000
Acarbose 的成年哺乳动物寿命正例边界 20260426001814000
FGF21 的成年哺乳动物硬终点正例与语境限制 20260426001210000
FGF21 的非胸腺硬终点证据边界 20260426000731000
FGF21 不是通用免疫长寿瓶颈，而是局部胸腺 niche 入口 20260426000512000
GH/IGF-1 轴的成年哺乳动物硬终点审计门槛 20260426000307000
feature list 支付能力文案不能当页面级 checkout 证据 20260426000015000
多靶点组合的降权与升级门槛 20260425235917000
咨询型公开定价页一页式 SOP 20260425235632000
咨询型公开定价页审页模板 20260425235509000
全因子设计是估计组合交互项的最低要求 20260425235416000
咨询型公开定价页模板的真实校准 20260425235115000
公开定价页审页报告的最小交付包 20260425234911000
组合组优于单药组仍不足以证明超加和协同 20260425234434000
公开定价页的真实支付路径判读 20260425234410000
组合干预的协同判定不能只看组合组更好 20260425234306000
公开定价页的可执行购买路径锚点 20260425234231000
mitophagy / TFEB / lysosomal biogenesis 的成年哺乳动物寿命证据边界 20260425233850000
标题正例但正文近失配的快速判别 20260425233416000
标题正例但正文近失配的排除模板 20260425233217000
PubMed 题名/摘要级检索的证据边界 20260425232651000
HSP UPR ER stress ERAD 的成年哺乳动物硬终点边界 20260425232531000
ER stress UPR not yet baseline-positive as a mammalian longevity node 20260425232356000
TFEB HSF1 proteasome autophagy 成年哺乳动物硬终点审计边界 20260425231538000
公开定价页的页面级 checkout 判读 20260425231411000
自噬增强正例审计的解除抑制边界 20260425231403000
Proteostasis augmentation is not yet baseline-positive as a mammalian longevity node 20260425231119000
TFEB 的成年哺乳动物硬终点证据边界 20260425230947000
HSF1 的长寿证据边界 20260425230820000
公开定价页的支付闭环必须区分产品内收款能力与页面级回款闭环 20260425230328000
成年哺乳动物自噬增强候选的证据分级 20260425225000000
组织特异递送候选的人类功能硬终点稀缺性 20260425224917000
体外与器官类系统中也未检出 senolytic→OSK 原始顺序实验 20260425224235000
皮肤创面预设功能终点模板不等于长寿正例 20260425223759000
预防性 longevity 服务的企业入口分型 20260425223112000
B2B 福利/企业套餐型服务的企业入口模式 20260425222929000
另一眼科局灶系统中的 ROCK 抑制硬终点边界 20260425222711000
口腔/牙龈黏膜中的 ROCK 抑制目前未检出可比硬终点正例 20260425222550000
青光眼/小梁切除术中的 ROCK 抑制更像术后辅助而非角膜级硬终点 20260425222415000
皮肤创面与关节腔 ROCK 抑制的硬终点审计空缺 20260425222109000
角膜作为局灶再生硬终点正例 20260425222017000
主 payer 的公开路径识别规则 20260425221527000
局部 rapamycin 的硬终点审计空集 20260425221251000
局部 rapamycin 作为组织特异递送候选的证据边界 20260425220843000
公开标价 longevity 服务的真实付费方结构 20260425220828000
预防性 longevity 服务的典型付费方结构 20260425220542000
局部 ROCK 抑制作为局灶再生硬终点正例 20260425215930000
局部 metformin 作为组织特异递送候选的证据边界 20260425215123000
IL-17 / IL-1 作为局部炎症轴候选的证据边界 20260425213936000
senolytic 作为组织特异递送候选的证据边界 20260425213802000
IL-11 组织特异性递送的证据空缺 20260425213426000
IL-11 终末表型分层审计模板 20260425213024000
IL-11 修复代价的证据地图 20260425212718000
digital health WTP depends on prior experience and health state 20260425212107000
更接近现金回款的交付形态应按现金速度而非总价排序 20260425211751000
IL-11 longevity candidacy must be split by tissue-specific tradeoffs 20260425211443000
IL-11 pleiotropy audit should be split by terminal phenotype class 20260425211111000
预防性 longevity 服务的公开购买路径结构 20260425210754000
IL-11 的因果强度高于许多炎症候选，但比较时仍需分层 20260425205727000
rapamycin 与自噬的单终点比较必须先收敛到共同最窄交集 20260425205350000
rapamycin 与自噬的单终点比较门槛 20260425205231000
rapamycin 的直接 organism-level 锚点 20260425204608000
rapamycin 的小鼠寿命/健康寿命正例 20260425204342000
自噬与主轴候选的比较结论 20260425203752000
候选主轴的 provisional ranking 与升级条件 20260425203226000
公开购买路径密度的最小判定口令 20260425200201000
公开购买路径密度的评分/分档规则 20260425194855000
公开购买路径密度的一页式审页模板 20260425194650000
公开购买路径密度的最小打分表 20260425194201000
成年哺乳动物自噬增强正例的统一审计边界 20260425192603000
senolytic→OSK 的 ex vivo 边缘题录审稿结论 20260425192412000
senolytic→partial reprogramming 的 ex vivo 序贯证据门槛 20260425192152000
ABT-263 后炎症与修复回落必须靠纵向时间序列判定 20260425191600000
序贯干预中的 schedule anchor 与 recovery anchor 必须分离 20260425190835000
ABT-263→OSK 间隔的保守锚定原则 20260425185656000
topical ABT-263 的皮肤生物学恢复缓冲期 20260425185440000
零EV来源占比误差预算表 20260425181651000
皮肤中 senolytic→OSK 的最小实验蓝图 20260425181207000
来源占比误差会把零EV边界直接推翻 20260425181053000
渠道零EV门槛表（保守重算） 20260425180829000
部分重编程 go/no-go 判据与安全边界 20260425180607000
零EV边界应以来源混合区间而非单点成交率表达 20260425175436000
零EV 边界的来源混合重算公式 20260425175246000
顺序联合比较必须先锁组织与读出 20260425174929000
senolytic→OSK 顺序联合的原始证据边界 20260425174632000
自噬轴候选应分为“独立干预、上游状态与 readout”三层 20260425174343000
成年哺乳动物自噬增强候选的审计结论 20260425174141000
自噬增强原始正例检索的噪音类型 20260425173833000
TFEB-mediated autophagy can extend lifespan in middle-aged mice 20260425173437000
20人样本一页式决策器 20260425173357000
20人样本下的分段门槛决策表 20260425173312000
各渠道的零EV成交率门槛 20260425172711000
获客渠道的线索温度阶梯 20260425172527000
骨相关系统中的 senolytic→OSK 顺序实验仍未检出 20260425171453000
非糖尿病急性骨折/肌腱修复中的 senolytic 证据缺口 20260425171209000
急性骨/肌腱修复中的 senolytic 方向依赖组织与背景 20260425171003000
senolytic 在非糖尿病急性神经损伤中可能促再生而非单向延迟修复 20260425170752000
senolytic 对急性修复并非必然有害 20260425170413000
单一组织内 senescence 负担态与生态位态的可证伪判别框架 20260425165902000
warm lead 原始记录的外部载体先于核验 20260425165018000
骨组织中 OSK 与 senolytic 的最小代理终点 20260425164755000
Autophagy is a baseline-positive mammalian longevity node 20260425163912000
自噬轴第三条成年哺乳动物原始正例的审计边界 20260425163721000
warm lead 的最低回复阈值由资格率与成交率共同决定 20260425163654000
间接自噬关联证据不应计入直接自噬增强正例 20260425162314000
Heat-shock/chaperone augmentation is not yet baseline-positive as a mammalian longevity node 20260425154317000
Proteasome augmentation is not yet baseline-positive as a longevity node 20260425154052000
Mitochondrial interventions have direct lifespan-endpoint positives, but evidence is heterogeneous 20260425153808000
Autophagy enhancement is not yet baseline-positive like rapamycin/mTOR 20260425153601000
Rapamycin is a baseline-positive specific node; autophagy and mitochondria are not automatically longevity candidates 20260425153226000
mTOR/rapamycin 优先于泛化自噬/线粒体作为长寿候选 20260425152830000
IL-11 的寿命/健康寿命效应大小与证据边界 20260425152333000
IL-11 修复代价的直接成人哺乳动物原始反例仍未检出 20260425151726000
Adult-mammal IL-11 inhibition: direct bone-homeostasis harm, fracture/wound evidence still missing 20260425151443000
IL-11 longevity benefit must be decomposed into immune/inflammatory and tissue-tradeoff components 20260425150607000
IL-11 currently ranks above other screened immune/inflammation axes because it has direct mammalian healthspan/lifespan evidence 20260425150330000
补体级联仍未跨过通用长寿瓶颈门槛 20260425150146000
IL-1/MyD88 outranks TNF/IL-6 as an upstream screening candidate, but not as a universal bottleneck 20260425145846000
Complement cascade remains a high-potential but not yet universal longevity bottleneck 20260425145530000
TNF/IL-6 are low-priority control axes in longevity bottleneck screening 20260425145355000
cGAS-STING is a strong but context-dependent aging node, not yet a universal longevity bottleneck 20260425145335000
type I interferon / JAK-STAT is an upstream amplifier, not a default universal longevity bottleneck 20260425145224000
Thymic source restoration is a strong immune upstream entry, but not yet a universal longevity bottleneck 20260425144604000
TNF/IL-6 are context-specific inflammaging mediators, not universal longevity bottlenecks 20260425144110000
cGAS-STING is an upstream inflammaging amplifier, but not yet a universal longevity bottleneck 20260425143829000
NLRP3 is a strong aging node but still not clearly a universal longevity bottleneck 20260425143408000
资源撮合的杠杆属性：放大器优先，起手式谨慎 20260425143144000
complement 轴是高潜力候选但尚非 universal longevity bottleneck 20260425143032000
交易要先覆盖波动与摩擦 20260425143008000
投资交易的可持续性取决于边际优势是否覆盖波动与摩擦 20260425142949000
赚钱路径的通用排序：先现金流、后可复制业务、再资产/期权 20260425142251000
IL-1 is a strong upstream hematopoietic inflammaging loop, but not yet a universal longevity bottleneck 20260425142133000
成年啮齿类骨折愈合中的 IL11/IL11RA1 直接因果证据仍未检出 20260425140608000
IL-11 骨折愈合原始因果证据仍未检出 20260425140012000
IL-11 inhibition: bone-homeostasis evidence is direct, fracture-healing evidence remains missing 20260425135719000
Adult-mammal IL-11 inhibition has clear bone-homeostasis consequences, but direct fracture/wound inhibition evidence is sparse 20260425135357000
IL-11 still needs a pleiotropy tradeoff audit before universal-bottleneck promotion 20260425134905000
IL-6 trans-signaling is a plausible inflammaging axis, but not a universal longevity bottleneck 20260425134712000
IgG/FcRn is a strong immune age-amplifying axis, but not yet a universal longevity bottleneck 20260425134301000
IL-1 outranks TNF and type I IFN as an upstream immune loop, but still falls short of a universal longevity bottleneck 20260425133745000
IL-11 is a strong candidate but not yet a universal bottleneck 20260425133514000
IL-17 / Th17 is a context-dependent inflammaging axis, not a universal longevity bottleneck 20260425133233000
IL-11 remains the current top immune/inflammation longevity candidate, but not yet a universal bottleneck 20260425132624000
C1q brain aging mechanism is informative but still insufficient for universal longevity candidacy 20260425131714000
IL-11 is currently the strongest immune/inflammation longevity candidate in the screening set 20260425131144000
IgG is a strong age-amplifying node, but not yet a universal longevity bottleneck 20260425130909000
Antibody / IgG accumulation is a strong age-amplifying node, but not yet a universal longevity bottleneck 20260425130643000
trained immunity is a functional defense amplifier, not a higher-priority longevity bottleneck than thymic source restoration 20260425130412000
IL-1 / emergency myelopoiesis is upstream of aged HSC bias, but not yet a universal longevity bottleneck 20260425125943000
type I interferon / JAK-STAT chronic activation is strong but context-dependent, not yet a universal bottleneck 20260425125646000
C1q is aging-associated but not yet a universal longevity bottleneck 20260425125313000
IL-11 is a strong lifespan-positive inflammaging node, but still not yet a universal immune bottleneck 20260425124410000
NLRP3 is context-dependent longevity-positive, not yet a universal bottleneck 20260425051109000
单组织寿命正例不足以把炎症轴抬升为通用长寿瓶颈 20260425050954000
HSC/髓系偏置尚不能压过胸腺源恢复的免疫长寿排序 20260425050727000
局部语境决定抗衰老信号是否成立 20260425050544000
Source-restoration immune entries outrank peripheral T-cell quality control when only the former has healthspan extension 20260425050521000
Mature T-cell quality control usually ranks below thymic source restoration as a longevity entry 20260425050406000
免疫长寿入口的上游性排序：补给源 > 外周质量控制 > 局部 niche 维护 20260425050257000
Peripheral T-cell quality control can reach frailty, but not yet lifespan 20260425050159000
Peripheral T-cell quality control can reach frailty, while thymic regeneration remains mainly immune-readout level 20260425044850000
T-cell Bcl-xL is a concrete peripheral quality-control example, but still not a validated universal longevity bottleneck 20260425044154000
Peripheral lymph node niche repair is a lower-rank immune rejuvenation entry than thymic regeneration 20260425043703000
Peripheral lymph node niche is a reversible immune entry, but not yet higher-leverage than thymic involution 20260425043458000
Thymic involution remains the strongest reversible immune entry, but not yet a validated longevity bottleneck 20260425042531000
IL-1 emergency myelopoiesis is upstream but not yet validated as a longevity bottleneck 20260425042245000
Trained immunity is not yet a validated longevity bottleneck 20260425042105000
Thymus regeneration improves immune readouts but not yet lifespan evidence 20260425041751000
Immune rejuvenation can improve systemic aging phenotypes via thymic or peripheral routes 20260425041629000
Immune interventions can improve systemic aging phenotypes, but not always via thymic regeneration 20260425041447000
Immune longevity candidate ranking: thymic involution first, readouts later 20260425041227000
Thymic involution can be experimentally reversed to restore naive T-cell output in aged mice 20260425040945000
Netrin-1 可作为老化骨髓 niche 的可逆上游杠杆 20260425040329000
Blood-aging candidate ranking: HSC exhaustion over CHIP; cell competition as framework 20260425040156000
cell competition is a generic tissue-level quality-control framework 20260425040057000
Bone marrow niche rejuvenation can restore aged HSC fitness 20260425035840000
年龄相关克隆现象优先视为读出而非总瓶颈 20260425035640000
CHIP 更适合作为 HSC aging 的读出而非单一上游瓶颈 20260425035624000
CDKN2A-OSK 在皮肤创面中的 FOSL1/迁移信号更应默认按间接效应解释 20260425035159000
CDKN2A-OSK 在人皮肤创面中的直接效应与微环境间接效应应分层判断 20260425034935000
FOSL1 不能被当成 CDKN2A-OSK 直接驱动角质形成细胞迁移的证据 20260425034652000
CDKN2A-OSK 在人皮肤伤口边缘更像编辑炎症/应激状态，而非直接的增殖开关 20260425034427000
重编程效应要拆成炎症编辑与增殖激活两条轴 20260425034206000
partial reprogramming 在人皮肤修复中更像炎症/应激状态编辑，而非增殖开关 20260425034137000
partial reprogramming 在皮肤修复中更像炎症/应激状态编辑 20260425033952000
human skin wound-healing roadmap cleanly separates acute-support and chronic-failure programs 20260425033600000
修复失败常是跨细胞协同失配 20260425033050000
chronic wound failure programs clarify which senescence states are pathological 20260425033027000
acute skin wound healing contains distinct senescent subpopulations with opposite effects 20260425032856000
acute cutaneous wound healing is a clear example of context-dependent senescence 20260425032612000
partial reprogramming can improve regeneration by remodeling the extrinsic niche 20260425032418000
senolysis before OSK may remove a pro-reprogramming niche in some contexts 20260425032136000
同组织 senolytic 预处理后再做 OSK 的原始实验仍未检出 20260425031957000
senolytic 预处理与 OSK 增效证据未检出 20260425031913000
另一单一组织中的 senolytic→OSK 顺序组合仍未检出 20260425031525000
顺序联合比单药 head-to-head 更有信息量 20260425030652000
Topical ABT-263 treatment reduces aged skin senescence and improves subsequent wound healing 20260425030358000
皮肤 OSK vs ABT-263 参数对齐表（补全版） 20260425030211000
皮肤 OSK vs ABT-263 可执行参数表（反证版） 20260425025941000
OSK vs ABT-263 的对齐/不对齐清单（皮肤场景） 20260425025615000
Topical ABT-263 in aged mouse skin: original study and readouts 20260425025523000
Targeted partial reprogramming of age-associated cell states: skin-relevant OSK parameters 20260425025310000
OSK vs senolytic direct head-to-head remains sparse across tissues 20260425022737000
皮肤中 OSK vs ABT-263 的原始 head-to-head 未检到 20260425022429000
同组织头对头证据比并列正例稀缺 20260425021819000
统一比较组织的选择原则：皮肤是当前可用候选面板 20260425021710000
局部正例不能直接外推为长寿主路线代表性 20260425021446000
同一读出面板下比较长寿瓶颈候选的工程准则 20260425021221000
功能性与组织完整性读出：部分重编程验证的最小并列面板 20260425020502000
表观遗传主读出设计原则：组织特异DNAm时钟优先 20260425020313000
Partial reprogramming 的优先干预模态选择原则 20260425020147000
表观遗传信息损失的可检验干预与读出方案 20260425015926000
Epigenetic information loss as a testable longevity bottleneck 20260425015600000
三态判别协议的压力测试结果 20260425015339000
旧前缀+下一前缀联合生存刻画中性（small-case） 20260425014335000
旧前缀可替代嵌入不足以判别中性 20260425013950000
单一局部特征通常只能给出必要条件 20260425013436000
单侧交换位置可压缩为局部窗口 20260425010941000
交换不依赖右侧的充分条件 20260425005858000
左侧一次相邻交换的切分判定复用模板 20260425005439000
Iter-4360dd15-0186-fact-left-prefix-consumption-cut 20260425002431000
Iter-4360dd15-0178-fact-support-contained-window-decidable-audit 20260424234738000
Iter-4360dd15-0174-fact-exhaustive-reachability-audit 20260424233953000
Iter-4360dd15-0173-fact-support-contained-boundary-consistency 20260424233814000
Iter-4360dd15-0172-fact-accept-support-contained-boundary-consistency 20260424233727000
Iter-4360dd15-0171-fact-minimal-counterexample-support-contained-window 20260424233529000
Iter-4360dd15-0166-fact-minimal-insertion-reorder-counterexample 20260424232532000
Iter-4360dd15-0165-method-content-subsequence-local-insertion 20260424232430000
重写判定要分层 20260424231903000
重写判定要用二层信号 20260424231655000
重写判定必须分层 20260424231556000
Iter-4360dd15-0160-method-pmc4083033-rewrite-v2 20260424231537000
Iter-4360dd15-0159-lesson-rewrite-threshold-failure 20260424231322000
Iter-4360dd15-0158-method-pmc4083033-sentence-rewrite-template 20260424231132000
Iter-4360dd15-0157-fact-pmc4083033-word-diff 20260424231031000
Iter-4360dd15-0156-fact-pmc4083033-xml-offsets 20260424230924000
Iter-4360dd15-0155-fact-pmc4083033-xml-coordinates 20260424230807000
BOLERO-2 PMCID and abstract PFS sentence directly verified from PMC 20260424220204000
BOLERO-2 PMID PMCID DOI confirmed from Europe PMC and PMC 20260424220045000
BOLERO-2 主文数值与 PMID/DOI 的直接抽取（Springer OA + NCBI export） 20260424215916000
BOLERO-2 主要终点具体结果数值（Springer OA） 20260424215736000
BOLERO-2 可访问非-NEJM 设计/终点证据已补齐 20260424215252000
BOLERO-2 PMID 22149876 的可访问非-NEJM 设计/终点复核 20260424215102000
BOLERO-2 PMID 22149876 的第二独立复核来源与 primary endpoint 20260424214827000
BOLERO-2 原始主报告 PMID 22149876 与 primary endpoint PFS 20260424214522000
PMID 22149876 is the original BOLERO-2 phase 3 primary report, not 24267730 20260424214401000
PMID 24267730 is a subgroup analysis, not the first original human trial 20260424214147000
Iter-4360dd15-0106-four-candidate-audit 20260424213752000
Iter-4360dd15-0104-three-remaining-candidates-are-not-original-first-reports 20260424213638000
Iter-4360dd15-0103-EuropePMC-38310895-reference-parser-and-candidate-shortlist 20260424213315000
Iter-4360dd15-0100-human-trial-vs-non-original-screening-of-38310895-references 20260424212530000
Iter-4360dd15-0098-EuropePMC-extract-human-trial-PMIDs 20260424212055000
PMID 22367193 is cardiac-repolarization safety, not longevity evidence 20260424210833000
PMID 24691032 is muscle-protein-synthesis endpoint, not longevity evidence 20260424210355000
PMID 22115710 is phase I ocular safety study, not longevity evidence 20260424210145000
PMID 29408453 is feasibility/safety pilot, not direct longevity evidence 20260424210012000
PMID 33977284 is RTI incidence endpoint, not direct longevity evidence 20260424204839000
PMID 25540326 is immune-response endpoint, not longevity evidence 20260424204718000
PMID 27883166 is a pilot safety feasibility trial not direct longevity evidence 20260424204543000
PEARL trial is not direct longevity evidence 20260424203525000
Iter-4360dd15-0078-two-pmid-evidence-verification 20260424203242000
Iter-4360dd15-0077-unified-longevity-classification-four-pmids 20260424203137000
Iter-4360dd15-0075-abstract-field-extraction-two-pmids 20260424202951000
Iter-4360dd15-0069-standardized-audit-table-two-trials 20260424201621000
Iter-4360dd15-0068-abstract-endpoint-extraction 20260424201407000
Iter-4360dd15-0067-abstract-endpoints-aging-criteria 20260424201141000
Iter-4360dd15-0066-TierA-abstracts-and-endpoints-for-aging-criteria 20260424200925000
Iter-4360dd15-0065-minimal-relevance-decision-rules-for-retained-mtor-trials 20260424200748000
Iter-4360dd15-0064-relevance-tiering-10-pmids 20260424200602000
Iter-4360dd15-0063-10-pmid-audit-table 20260424200432000
Iter-4360dd15-0062-pubmed-title-verification-10-pmids 20260424200328000
Iter-4360dd15-0061-candidate-audit-10-remaining-pmids 20260424200221000
PMID 38310895 is a review, not a primary trial 20260424200109000
PMID 35040506 longitudinal analysis is embedded in primary trial 20260424195939000
Iter-4360dd15-0058-longevity-evidence-proximity-tagging 20260424195827000
Iter-4360dd15-0057-study-design-taxonomy-for-retained-trials 20260424195711000
Iter-4360dd15-0056-pubmed-boundary-confirmation 20260424195548000
Iter-4360dd15-0053-final-audit-14-candidates 20260424194939000
Iter-4360dd15-0052-rapamycin-older-cohort-pmid-mapping 20260424194711000
Iter-4360dd15-0048-crossref-trialish-candidate-extraction 20260424194106000
PMID 38310895 access topology verified 20260424193545000
Iter-4360dd15-0042-crossref-family-collapse-10-families 20260424192619000
Iter-4360dd15-0040-crossref-trialish-family-taxonomy 20260424192051000
Iter-4360dd15-0039-crossref-candidate-family-critique 20260424191812000
Iter-4360dd15-0038-crossref-human-trial-filter-method 20260424191618000
2024 rapamycin systematic review: abstract-level constraints and what remains missing 20260424175824000
Added included ADPKD rapalog trial CRAD001ADE12 and its body-weight endpoint 20260424174657000
Rapamycin human trials: completed studies table from PMC review 20260424174352000
Human longevity interventions evidence maturity matrix 2026-04-25 20260424173237000
Prime-100 mod6 minimal transition table verified 20260424171809000
Prime-100 gap motif compressed verified 20260424171706000
Prime-100 pattern gaps verified 20260424171335000
Prime-100 pattern last digit verified 20260424171237000
Prime-100 pattern mod 6 verified 20260424171150000